Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Therapeutic TRPA1 Mechanism-Based Treatment of Chemotherapeutic-Induced Neuropathic Pain

Award Number: R43CA210759
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/21/2017
PERIOD OF PERFORMANCE END DATE: 08/31/2018

Group Awards By:

View Award Description

Therapeutic TRPA1 Mechanism-Based Treatment of Chemotherapeutic-Induced Neuropathic Pain - Abstract Cancer patients treated with many widely used chemotherapeutic agents, including paclitaxel (PAC) and oxaliplatin (OXA), frequently develop chemotherapy-induced peripheral neuropathy (CIPN) that may lead to dose reduction, dosing schedule changes and termination of treatment. In some patients, acute peripheral neuropathy (PN) can transition into chronic PN lasting well beyond termination of chemotherapy. Currently, there are no drugs to prevent CIPN and the therapeutic “off-label” use of existing analgesics is not effective. Recent evidence suggests that a member of the thermo-sensitive TRP ion channel family is responsible for pain generation arising from the affected sensory neurons. We have identified the transient receptor potential, subfamily A, member 1 (TRPA1), as a promising target for novel analgesic drugs to treat or prevent CIPN. TRPA1 is activated by noxious cold and ROS, consistent with rapidly induced cold allodynia symptoms found in CIPN patients. The goal of this proposal is to develop a novel therapeutic approach based a new molecular mechanism that targets this key molecule involved in acute and chronic responses to CIPN. We propose to develop a novel, therapeutic small molecule functional antagonist of TRPA1 for the treatment of CIPN. TRPA1 receptor-channels serve a highly specific function on sensory nerve fiber endings that detect and transmit the sensations of pain and hyperalgesia in response to nerve injury. PAC or OXA treatment induces upregulation and sensitization of TRPA1. Our preliminary in vivo data shows that TRPA1 antagonists reverse neuropathic pain behaviors in a translational paclitaxel-CIPN model. The overall goal is to develop a TRPA1 antagonist delivered in combination with either PAC or OXA that is effective in blocking TRPA1 activation during CIPN. Our studies will first determine the potency and efficacy of TRPA1 antagonists to inhibit PAC- and OXA- induced activation in cultured DRG neurons. Second, the pharmacokinetics of three TRPA1 antagonists will be determined to enable dose selection for in vivo efficacy studies. Third, dose-response profiles for TRPA1 antagonists will be determined in translational rat PAC- and OXA-CIPN models using acute and chronic dosing. The final aim is to determine if a TRPA1 antagonist administered before and during PAC or OXA dosing can prevent induction of CIPN. The final Phase 1 milestone is to deliver an advanced preclinical candidate having pharmacological properties necessary for a full development program in Phase 2.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$64,945 )
2023	2017	ALGOMEDIX, INC.	16212 BOTHELL EVERETT HWY	MILL CREEK	WA	98012	SNOHOMISH	USA	Cancer Treatment Research	000	1	10/1/2022	NEW	-$64,945
														Subtotal = -$64,945

Issue Date FY: 2019 ( Subtotal = -$28,007 )
2019	2017	ALGOMEDIX, INC.	16212 BOTHELL EVERETT HWY	MILL CREEK	WA	98012	SNOHOMISH	USA	Cancer Treatment Research	000	1	2/21/2019	NEW	-$28,007
														Subtotal = -$28,007

Issue Date FY: 2017 ( Subtotal = $291,147 )
2017	2017	ALGOMEDIX, INC.	16212 BOTHELL EVERETT HWY	MILL CREEK	WA	98012	SNOHOMISH	USA	Cancer Treatment Research	000	1	9/21/2017	NEW	$291,147
														Subtotal = $291,147

Grand Total All Awards = $198,195

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Therapeutic TRPA1 Mechanism-Based Treatment of Chemotherapeutic-Induced Neuropathic Pain

Award Number: R43CA210759

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/21/2017

PERIOD OF PERFORMANCE END DATE: 08/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer